MIRA Pharmaceuticals Valuation

Is K6S undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of K6S when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: K6S (€1.61) is trading below our estimate of fair value (€18.96)

Significantly Below Fair Value: K6S is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for K6S?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for K6S. This is calculated by dividing K6S's market cap by their current preferred multiple.
What is K6S's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$30.91m

K6S key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does K6S's PB Ratio compare to its peers?

The above table shows the PB ratio for K6S vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	5.2x
SBX SynBiotic	2x	107.0%	€31.9m
B8FK Biofrontera	1x	n/a	€17.5m
HIGH Cantourage Group	1.3x	110.6%	€59.4m
0RX Redx Pharma	16.6x	-22.3%	€65.0m
K6S MIRA Pharmaceuticals	13.6x	14.4%	€30.9m

Price-To-Book vs Peers: K6S is expensive based on its Price-To-Book Ratio (13.6x) compared to the peer average (5.2x).

Price to Earnings Ratio vs Industry

How does K6S's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.9%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: K6S is expensive based on its Price-To-Book Ratio (13.6x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is K6S's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

K6S PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	13.6x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate K6S's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst K6S forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	€1.61	€11.13 +591.1%	35.2%	€16.34	€6.91	n/a	3
Oct ’25	€1.18	€10.43 +784.0%	31.8%	€14.75	€6.71	n/a	3
Sep ’25	€1.56	€10.43 +568.7%	31.8%	€14.75	€6.71	n/a	3
Aug ’25	€1.80	€12.23 +579.2%	24.5%	€15.22	€9.23	n/a	2
Jul ’25	€0.58	€12.33 +2,026.6%	24.5%	€15.36	€9.31	n/a	2
Jun ’25	€0.72	€12.44 +1,627.5%	24.5%	€15.49	€9.39	n/a	2
May ’25	€0.77	€12.44 +1,515.3%	24.5%	€15.49	€9.39	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.